A patient with established cognitive decline who develops recurrent visual hallucinations and spontaneous changes in alertness raises a focused question: do these count as two core features of dementia with Lewy bodies (DLB)? If the person also meets the clinical definition of dementia, the combination can support a clinical diagnosis of probable DLB—and should change how Family Medicine approaches antipsychotic medications.
The purpose here is not to treat visual hallucinations as a diagnosis by themselves. It is to decide when this particular pattern, in the right cognitive and functional context, meaningfully shifts the dementia formulation and medication-safety plan.
Verify dementia and characterize both clues
DLB criteria require dementia: progressive cognitive decline substantial enough to interfere with usual daily activities or social or occupational function. A screening score alone cannot establish that threshold. Ask the patient and, with permission, someone who knows them well what has changed from baseline and which activities—such as managing medicines, finances, meals, or transportation—now require help.
Memory loss need not be the most prominent early problem. Attention, executive skills, and visual processing may be disproportionately affected; that profile can support the formulation, but it is not itself a required DLB criterion. Mixed Alzheimer and Lewy-related pathology can occur, so a DLB pattern does not rule out a contribution from Alzheimer disease.
For the two symptoms in this scenario, get specifics rather than accepting labels. Ask whether the visual experiences recur and are detailed or well formed—often people or animals—and ask a care partner for examples. For “fluctuating alertness,” clarify whether there are spontaneous episodes of marked inattention, drowsiness, staring, or disorganized speech, and how these differ from the person’s usual state.
Count the core features accurately
The consensus criteria recognize four core clinical features. Hallucination content and collateral history help establish whether a feature is actually present; they do not add extra points to the count.
| Core feature | What to establish | Common overcall |
|---|---|---|
| Fluctuating cognition | Spontaneous, delirium-like changes in attention, cognition, or arousal; document concrete examples over time | Calling any bad day or a single episode of confusion a characteristic fluctuation |
| Recurrent visual hallucinations | Repeated, detailed visual experiences, often of people or animals | Treating any visual misperception—or one new episode during illness—as this feature |
| Spontaneous parkinsonism | At least one cardinal motor sign: bradykinesia, rest tremor, or rigidity | Counting slowed movement caused by medication, arthritis, or another condition without assessing the cause |
| REM sleep behavior disorder | A history of acting out dreams, ideally corroborated by a bed partner; consider mimics | Assuming restless sleep alone establishes the disorder |
Dementia is essential; the four items in the table are core features, not prerequisites that must all be present. In someone who meets the dementia requirement, two or more core features support probable DLB under the clinical criteria. One core feature alone, without an indicative biomarker, supports possible DLB; one core feature together with an indicative biomarker can support probable DLB. Thus, recurrent well-formed visual hallucinations plus documented cognitive fluctuations can meet the clinical threshold even if parkinsonism has not been observed. “Probable” describes a clinical category; it is not proof of pathology.
Severe sensitivity to antipsychotic medication is a supportive feature, not a core feature or a requirement. Its absence does not rule out DLB, and a past severe reaction should raise concern without serving as a stand-alone diagnosis. Fluctuations may also appear in advanced stages of other dementias, so their timing and quality matter; the pattern is more informative when features emerge earlier in the cognitive course.
If parkinsonism is also present, the one-year convention helps distinguish DLB from Parkinson disease dementia: dementia that starts before, or within a year of, motor symptoms is classified as DLB; dementia developing after well-established Parkinson disease is classified as Parkinson disease dementia. The consensus group retains this useful clinical convention while recognizing that the cutoff is arbitrary, not a biological dividing line.
Keep delirium in the assessment
DLB fluctuations can look delirium-like, but that does not make every change in alertness part of the dementia. A new or sharply worse change over hours to days—especially with inattention, altered awareness, illness, a medication change, or another acute trigger—calls for assessment for delirium. Compare the person with their usual cognitive and functional baseline using a knowledgeable informant; do not assume that a known or suspected DLB explains the change away.
The conditions can coexist. A person with DLB can develop delirium, and treating a superimposed cause may improve an acute deterioration without removing the underlying cognitive pattern. Conversely, a stable history of recurrent fluctuations and hallucinations over the course of progressive dementia should not be relabeled as a series of unrelated acute psychiatric episodes without considering DLB.
Let recognition change the medication decision
Hallucinations can be vivid without being frightening or dangerous. Ask whether they distress the patient, prompt unsafe behavior, or create a risk of harm before treating them as a medication problem. Review the medication list and recent changes, and consider practical contributors such as illness, sleep disruption, and vision problems.
Dopamine-blocking antipsychotics can worsen parkinsonian motor symptoms in DLB; some people also have severe sensitivity reactions, including marked confusion or sedation. That risk makes a routine antipsychotic response to hallucinations a poor default, particularly with typical agents such as haloperidol. First consider non-drug approaches and address reversible contributors. If symptoms cause severe distress or pose a safety risk, weigh benefits and harms carefully and seek specialist input when feasible rather than treating the suspected DLB pattern as ordinary psychosis.
Family Medicine has a practical role before and after referral: document the patient’s baseline and functional history, assess for parkinsonism and dream enactment, reconcile medications, and make the suspected DLB pattern visible in the problem list and handoff. Specialist assessment can help when the diagnosis remains uncertain or biomarker testing is being considered; no single symptom or office screening score settles the subtype.
Practical takeaways
- DLB criteria require dementia that interferes with usual function; cognitive symptoms alone are not enough.
- Recurrent well-formed visual hallucinations and characteristic cognitive fluctuations are two core features. With dementia established, they support probable DLB even without parkinsonism.
- A new acute change still warrants assessment for delirium; delirium and DLB can coexist.
- Severe antipsychotic sensitivity is supportive, not required. Suspected DLB should prompt caution before prescribing dopamine-blocking medication.
